328233-30-3

Basic information

• Product Name: 1'-benzyl-6-methoxyspiro[isobenzofuran-1(3H),4'-piperidine]-3-one
• Synonyms: 1'-benzyl-6-methoxyspiro[isobenzofuran-1(3H),4'-piperidine]-3-one
• CAS NO: 328233-30-3
• Molecular Weight: 323.392
• Mol File: 328233-30-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1'-benzyl-6-methoxyspiro[isobenzofuran-1(3H),4'-piperidine]-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1'-benzyl-6-methoxyspiro[isobenzofuran-1(3H),4'-piperidine]-3-one(328233-30-3)
• EPA Substance Registry System: 1'-benzyl-6-methoxyspiro[isobenzofuran-1(3H),4'-piperidine]-3-one(328233-30-3)

Safety Data

• Hazardous Substances Data: 328233-30-3(Hazardous Substances Data)

Upstream product

• 53416-46-9 2-(4-methoxyphenyl)-4,4-dimethyl-2-oxazoline 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Relevant articles and documents

Spiro compounds

Compounds of the general formula (I): wherein Ar1represents optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V, and W each independently represent nitrogen atom or optionally substituted methine group, where at least two of them represent the said methine group; X represents methine or hydroxy substituted methine; Y represents an optionally substituted imino or oxygen atom are described and claimed. These novel spiro compounds are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various kinds of cardiovascular disorders, central nervous system disorders, metabolic diseases and the like.

Spiro compounds

Spiro compounds of the general formula (I): wherein Ar1represents an optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V and W each represent a nitrogen atom or an optionally substituted methine group, wherein at least two of which represent said methine group; X represents methine; Y represents an optionally substituted imino or oxygen atom. These novel spiro compounds exhibit neuropeptide Y receptor (NPY) antagonistic activities and are useful as agents for the treatment of various diseases related to NPY, for example, cardiovascular disorders, central nervous system disorders, metobolic diseases and the like.